Related Experiment Videos
GroupBuild: a fragment-based method for de novo drug design
1Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139-4211.
Journal of Medicinal Chemistry
|June 11, 1993
Summary
A new computational method, GroupBuild, designs novel drug molecules by assembling functional groups to fit enzyme active sites. This approach generates chemically sound, low-energy structures similar to known potent inhibitors.
Area of Science:
- Computational chemistry
- Medicinal chemistry
- Drug discovery
Background:
- De novo drug design aims to create novel molecules with desired properties.
- Enzyme active site interactions are crucial for drug efficacy.
- Existing methods may lack efficiency in generating chemically feasible structures.
Purpose of the Study:
- To introduce GroupBuild, a novel computational method for de novo drug design.
- To demonstrate the ability of GroupBuild to generate chemically reasonable and low-energy drug candidates that fit enzyme active sites.
Main Methods:
- GroupBuild utilizes a library of functional groups as building blocks.
- Structure generation can be initiated from user-defined enzyme seed atoms or an inhibitor core.
- Candidate fragments are evaluated using a molecular mechanics potential function for scoring and selection.
Main Results:
- GroupBuild successfully generated chemically reasonable structures tailored to enzyme active sites.
- The method produced molecules with good steric and electrostatic complementarity.
- Tests on HIV protease, FK506 binding protein, and human carbonic anhydrase yielded structures resembling known potent inhibitors.
Conclusions:
- GroupBuild is an effective computational tool for de novo drug design.
- The method facilitates the generation of novel, high-quality drug candidates by assembling functional groups.
- GroupBuild shows promise for accelerating the discovery of enzyme-targeted therapeutics.